Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

10x Genomics, Inc. Director's Dealing 2021

May 27, 2021

31830_dirs_2021-05-26_2541926f-1c7b-47ca-80bc-c10b1201dee6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-05-24

Reporting Person: Kosaraju Sridhar (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-05-24 Class A Common Stock S 400 $160.0513 Disposed 14600 Indirect
2021-05-24 Class A Common Stock S 700 $161.1507 Disposed 13900 Indirect
2021-05-24 Class A Common Stock S 300 $162.0533 Disposed 13600 Indirect
2021-05-24 Class A Common Stock S 100 $163.04 Disposed 13500 Indirect

Holdings (Non-Derivative)

Security Shares Ownership
Class A Common Stock 2833 Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Kosaraju Family Trust.

F2: This transaction was executed in multiple trades at prices ranging from $159.64 to $160.605. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: These shares are held by the Kosaraju Family Trust dated June 21, 2014, of which the Reporting Person is trustee (the "Kosaraju Family Trust").

F4: This transaction was executed in multiple trades at prices ranging from $160.66 to $161.635. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $161.91 to $162.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.